Companies

AstraZeneca investors call for change

Some of the biggest investors in AstraZeneca are calling for a radical shake-up of the board and executive team. Andrew Jack, pharmaceuticals correspondent, talks to the FT's Daniel Garrahan about the future for David Brennan as chief executive.